The aim of the thesis is to define the dependency of the classification of patients affected by neurodegenerative diseases on the choice of the parcellation atlas. Part of this thesis is the application of the functional connectivity analysis and the calculation of graph metrics according to the method published by Olaf Sporns and Mikail Rubinov [1] on fMRI data measured at CEITEC MU. The application is preceded by the theoretical research of parcellation atlases for brain segmentation from fMRI frames and the research of mathematical methods for classification as well as classifiers of neurodegenerative diseases. The first chapters of the thesis brings a theoretical basis of knowledge from the field of magnetic and functional magnetic resonance imaging. The physical principles of the method, the conditions and the course of acquisition of image data are defined. The third chapter summarizes the graph metrics used in the diploma thesis for analyzing and classifying graphs. The paper presents a brief overview of the brain segmentation methods, with the focuse on the atlas-based segmentation. After a theoretical research of functional connectivity methods and mathematical classification methods, the findings were used for segmentation, calculation of graph metrics and for classification of fMRI images obtained from 96 subjects into the one of two classes using Binary classifications by support vector machines and linear discriminatory analysis. The data classified in this study was measured on patiens with Parkinson’s disease (PD), Alzheimer’s disease (AD), Mild cognitive impairment (MCI), a combination of PD and MCI and subjects belonging to the control group of healthy individuals. For pre-processing and analysis, the MATLAB environment, the SPM12 toolbox and The Brain Connectivity Toolbox were used.

No description available.

Mänsklig utforskning av månen och Mars innebär stora utmaningar för människans fysiologi och hälsa på grund av de unika miljöfaktorer som följer av långvariga rymduppdrag. Rymdbiologiska experiment har blivit ett viktigt verktyg för att studera effekterna som mikrogravitation och rymdstrålning har på levande organismer, i syfte att förstå och minska dessa utmaningar. Sådana experiment ger forskarna möjlighet att få insikt i rymduppdragens inverkan på människans fysiologi och utveckla strategier för att motverka eventuella skadliga effekter. Dessutom ger rymdbiologiska experiment möjlighet att öka vår förståelse av grundläggande biologiska processer, inklusive mikrogravitationens effekter på celldifferentiering och vävnadsregeneration, med potentiella tillämpningar för både rymdforskning och för att förbättra människors hälsa på jorden. Särskilt studier av mikrogravitationens effekter på hjärncellerna har potentiella konsekvenser för neurodegenerativa sjukdomar som Alzheimers och Parkinsons sjukdom. Genom att analysera data som genererats från hjärnor hos möss som skickats ut i rymden med en ny R-mjukvara, ArchR, är det möjligt att belysa de mekanismer som ligger till grund för förändringar i hjärnans funktion och beteende hos astronauter under långvariga rymduppdrag. Genom att förstå dessa mekanismer kan man utveckla nya terapeutiska metoder för att behandla eller till och med förebygga dessa sjukdomstillstånd. Fortsatta investeringar i rymdbiologisk forskning är avgörande för att garantera säkerheten och framgången för framtida, långvariga rymdforskningsuppdrag för människor. Genom att integrera avancerad teknik, t.ex. användning av spatiell transkriptomik eller sekvensering med encellsupplösning, kan en omfattande förståelse av komplexa biologiska system tolkas. De potentiella fördelarna med rymdbiologisk forskning sträcker sig längre än till att bara förstå effekterna av rymdfärder på människans fysiologi, med konsekvenser för grundläggande biologiska processer och behandling av en rad neurologiska sjukdomar. / Human exploration of the Moon and Mars poses significant challenges to human physiology and health due to the unique environmental factors that accompany long-duration space missions. Space biology experiments have emerged as an essential tool for studying the effects of microgravity and space radiation on living organisms, in order to understand and mitigate these challenges. Such experiments provide researchers with the opportunity to gain insights into the impacts of prolonged exposure to outer space on human physiology, and develop strategies to counteract any harmful effects. Additionally, space biology experiments offer the potential to enhance our understanding of fundamental biological processes, including the effects of microgravity on cell differentiation and tissue regeneration, with potential applications for both space exploration and improving human health on Earth. Previous research indicated the regulation of similar biomarkers, studying the effects of microgravity on brain cells could offer valuable insights into the potential impact on neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. By analyzing data generated from the brains of mice that have been sent to space with a new R-software tool called ArchR, it is possible to elucidate the mechanisms underlying changes in brain function and behavior in astronauts during long-duration space missions. Understanding these mechanisms can inform the development of new therapeutic approaches to treating or even preventing these conditions. Continued investment in space biology research is critical to ensuring the safety and success of future long-term human space exploration missions. By integrating advanced technologies, such as the use of spatial transcriptomics or sequencing at the single-cell resolution, comprehensive understanding of complex biological systems can be interpreted. The potential benefits of space biology research extend beyond just understanding the effects of spaceflight on human physiology, with implications for fundamental biological processes and the treatment of a range of neurological diseases.

Modulation of the endocannabinoid system (ECS) is of great interest for its therapeutic relevance in several pathophysiological processes. The CB2 subtype is largely localized to immune effectors, including microglia within the central nervous system, where it promotes anti-inflammation. Recently, a rational drug design toward precise modulation of the CB2 active site revealed the novelty of Pyrrolo[2,1-c][1,4]benzodiazepines tricyclic chemotype with a high conformational similarity in comparison to the existing leads. These compounds are structurally unique, confirming their chemotype novelty. In our continuing search for new chemotypes as selective CB2 regulatory molecules, following SAR approaches, a total of 17 selected (S,E)-11-[2-(arylmethylene)hydrazono]-PBD analogs were synthesized and tested for their ability to bind to the CB1 and CB2 receptor orthosteric sites. A competitive [H]CP-55,940 binding screen revealed five compounds that exhibited >60% displacement at 10 μM concentration. Further concentration-response analysis revealed two compounds, and , as potent and selective CB2 ligands with sub-micromolar activities ( = 146 nM and 137 nM, respectively). In order to support the potential efficacy and safety of the analogs, the oral and intravenous pharmacokinetic properties of compound were sought. Compound was orally bioavailable, reaching maximum brain concentrations of 602 ± 162 ng/g (p.o.) with an elimination half-life of 22.9 ± 3.73 h. Whether administered via the oral or intravenous route, the elimination half-lives ranged between 9.3 and 16.7 h in the liver and kidneys. These compounds represent novel chemotypes, which can be further optimized for improved affinity and selectivity toward the CB2 receptor.

L’ataxie spinocérébelleuse de type 3, aussi connue en tant que la maladie de Machado-Joseph (MMJ), est une maladie qui se développe lorsqu’il y a une expansion des trinucléotides CAG dans la région codante du gène ATXN3. Ce dernier code pour la protéine ATXN3, une enzyme désubiquitinante avec des fonctions essentielles dans le maintien et la stabilisation de l’homéostasie protéique, la résistance au stress, la régulation de la transcription, la réparation de l’ADN, l’organisation du cytosquelette et la régulation de la myogenèse. Les principaux symptômes associés à cette maladie sont l’ataxie (le symptôme clé), une détérioration motrice progressive, la dystonie, la spasticité et la rigidité. Du fait de l’absence de thérapie spécifique et efficace pour traiter les individus atteints de la MMJ, l’approfondissement des connaissances liées à cette maladie est nécessaire. Le but de cette thèse est de comprendre davantage les mécanismes et voies de signalisations impliqués dans la pathologie de la MMJ. Pour atteindre cet objectif, à partir de notre modèle transgénique C. elegans MMJ, deux différents criblages ont été effectués : un criblage non biaisé de 3942 composés, et un criblage de modificateurs génétiques à base d’ARN interférent (ARNi) de 387 clones de facteurs de transcription. Le premier criblage nous a permis d’identifier cinq molécules prometteuses : l’alfacalcidol, le chenodiol, le cyclophosphamide, le fenbufen et le sulfaphenazole. Elles ont permis la restauration du défaut de la motilité, la protection contre la neurodégénérescence, et une augmentation de la durée de vie réduite chez les vers mutants. Trois parmi ces molécules, le chenodiol, le fenbufen et le sulfaphenazole ont démontré une nécessité de la présence de HLH-30/TFEB, un régulateur clé de l’autophagie et de la biogenèse lysosomale, pour leurs propriétés neuroprotectrices. Concernant le deuxième criblage, il nous a permis d’identifier un nouveau gène candidat impliqué dans la MMJ, fkh-2/FOXG1. L’inactivation de ce gène a entraîné une aggravation du défaut de la motilité, de la neurodégénérescence, et de la longévité réduite. À l’inverse, sa surexpression a restauré tous ces phénotypes, suggérant ainsi un rôle neuroprotecteur pour FKH-2/FOXG1 dans la MMJ. Le modèle C. elegans de MMJ et les criblages sont des outils puissants permettant un approfondissement des connaissances quant à la pathologie de la MMJ. Pour cette thèse, par l’identification des molécules neuroprotectrices et les facteurs de transcription HLH-30/TFEB et FKH-2/FOXG1, ayant des activités neuroprotectrices dans notre modèle lorsqu’ils sont surexprimés, il a été possible à mieux comprendre la pathologie de la MMJ, ainsi que les mécanismes et les voies de signalisation qui y sont impliqués. Ces découvertes sont prometteuses à investiguer dans des organismes modèles plus avancés, des applications précliniques et également, pour le développement de nouvelles interventions thérapeutiques pour la MMJ. / Spinocerebellar ataxia type 3, also known as Machado-Joseph disease (MJD), is a polyglutamine expansion disease arising from a trinucleotide CAG repeat expansion in the coding region of ATXN3. This gene encodes ATXN3 protein, a deubiquitinating enzyme, which is involved in protein homeostasis maintenance and stabilization, stress resistance, transcription regulation, DNA repair, cytoskeleton organisation and myogenesis regulation. The main symptoms associated with this disease are ataxia (the key symptom), progressive motor deterioration, dystonia, spasticity and stiffness. Due to our incomplete understanding of mechanisms and molecular pathways related to this disease, there are no therapies that successfully treat core MJD patients. Therefore, the identification of new candidate targets related to this disease is needed. The aim of this thesis is to gain insights into the pathways and mechanisms leading to MJD. In order to achieve this goal, we performed two different screens, a blind drug screen of 3942 compounds to identify protective small molecules, and a large-scale RNA interference (RNAi) screen of 387 transcription factor genes leading to identification of modifiers involved in our transgenic C. elegans MJD model. The first screen allowed us to identify five lead compounds restoring motility, protecting against neurodegeneration, and increasing the lifespan in mutant worms. These compounds were alfacalcidol, chenodiol, cyclophosphamide, fenbufen and sulfaphenazole. We then found that three of these compounds, chenodiol, fenbufen and sulfaphenazole required HLH-30/TFEB, a key transcriptional regulator of the autophagy and the lysosomal biogenesis, to complete their neuroprotective activities. The second screen brought us to identify a news hit gene candidate involved in MJD, fkh-2/FOXG1. We showed that inactivation of this gene enhanced the motility defect, neurodegeneration and reduced longevity in our MJD model. However, in opposite, its overexpression rescued all these phenotypes, suggesting a neuroprotective role for FKH-2/FOXG1 in MJD when overexpressed. C. elegans models for MJD and the screenings are promising tools to understand the mechanisms and pathways causing neurodegeneration, leading to MJD. In this study, we identified positively acting compounds that may be promising candidates for investigation in mammalian models of MJD and preclinical applications in the treatment of this disease. Also, we gained insights into the pathways of MJD and found that HLH-30/TFEB and FKH-2/FOXG1 are both implicated in MJD and have neuroprotective activities when they are overexpressed. These promising findings may aid the development of novel therapeutic interventions for MJD.

A alteração do tráfego mitocondrial em neurônios leva ao aumento do estresse oxidativo, privação de energia, deficiência da comunicação intercelular e neurodegeneração. Há evidências de que essas alterações de tráfego antecedem a morte neuronal associada à agregação proteica. Portanto, conhecer a relação entre a mobilidade mitocondrial e a formação de agregados proteicos pode ser um passo importante para o melhor entendimento dos mecanismos da neurodegeneração. Com isso, o objetivo do presente estudo é analisar a mobilidade das mitocôndrias em culturas de células do hipocampo, substância negra e locus coeruleus expostas a rotenona e MPTP, como agentes neurodegenerativos, e à rapamicina como ativador da autofagia. Um outro objetivo do estudo é avaliar o papel do cálcio (através do emprego de EGTA e ionomicina) no modelo experimental. Os resultados mostraram aumento da mobilidade mitocondrial no hipocampo e diminuição na substância negra, já no locus coeruleus houve aumento seguido de diminuição da mobilidade mitocondrial dependendo da concentração de rotenona. O emprego do EGTA e ionomicina mostra que a ação da rotenona sobre o tráfego mitocondrial envolve o cálcio, mas não se relaciona com uma possível alteração da integridade mitocondrial, já que não foi observada alteração no potencial de membrana mitocondrial. Foram também realizados experimentos a fim de avaliar a mobilidade mitocondrial em modelo utilizando rapamicina para ativar a autofagia e MPTP como indutor da neurodegeneração em culturas de células, onde foi observado aumento da mobilidade no hipocampo e no locus coeruleus quando exposto a rapamicina e aumento da mobilidade mitocondrial em cultura de células do hipocampo exposto a MPTP já no locus coeruleus houve uma diminuição significativa da mobilidade mitocondrial. Os resultados permitem concluir que o tráfego mitocondrial está alterado antes da agregação proteica podendo contribuir com a neurodegeneração / Altered mitochondrial traffic in neurons can lead to increased oxidative stress, energy deprivation, impaired intercellular communication and neurodegeneration. There are evidences mitochondria disturbing precedes neuronal death associated with protein aggregation. Therefore, the study of mitochondrial traffic and protein aggregation can be an important step towards a better understanding of the mechanisms of neurodegeneration. Thus, the aim of this study is to analyze mitochondria mobility in cultured cells of the hippocampus, substantia nigra and locus coeruleus exposed to rotenone and MPTP, as neurodegeneration-promoting agents, and rapamycin to activate autophagy. The other objective of the study was to analyze the role of calcium (through EGTA and ionomycin) in the experimental model. The results showed increased and decreased mobility mitochondrial in cells from hippocampus and substantia nigra, respectively, while the locus coeruleus cell culture has increased followed by decreased mitochondrial mobility depending upon rotenone concentration. The use of EGTA and ionomycin showed that alteration of mitochondrial traffic is associated with calcium, however it is not related with changes in mitochondrial membrane potential. Additional experiments were also conducted to assess mitochondrial mobility in a model using rapamycin to activate autophagy and MPTP to induce neurodegeneration in cell cultures. The results of these experiments showed increased mitochondrial mobility in the hippocampus and locus coeruleus when exposed to rapamycin; while MPTP also increased mitochondria mobility in hippocampal cell cultures, but decreased it in locus coeruleus. Results suggest that mitochondrial traffic is altered before protein aggregation, which may contribute to neurodegeneration

O desenvolvimento das doenças neurodegenerativas, como a doença de Alzheimer, está associado à presença de agregados proteicos contendo Tau hiperfosforilada (p-Tau). Esta disfunção da Tau leva a prejuízos na homeostase celular. Um mecanismo chave para diminuir e/ou prevenir os danos promovidos pelos agregados contendo Tau seria o estímulo de sua degradação. Neste sentido, a proposta do presente estudo foi analisar a degradação da proteína Tau após aumento da expressão exógena da cochaperona Bag-2, a qual influencia o sistema proteassomal de degradação; bem como avaliar a ativação dos sistemas de degradação, a fim de correlacionar estes sistemas em cultura de células primárias e organotípica do hipocampo de ratos. Os resultados mostraram que a rotenona foi capaz de aumentar os níveis de p-Tau e que a superexpressão de Bag-2, foi eficiente em prevenir e degradar a p-Tau. O mecanismo envolvido neste processo envolve a coordenação dos sistemas proteassomal e lisossomal, já que a Rab7 e a Rab24 (envolvidas na via lisossomal) mostraram-se diminuídas na fase que antecede a agregação proteica, enquanto houve aumento da Rab24 na presença dos agregados proteicos. Com relação ao peptídeo beta amiloide, foi demonstrado tendência de aumento de p-Tau acompanhado de diminuição da atividade proteassomal e lisossomal. O tratamento com PADK (ativador lisossomal) foi capaz de reverter este efeito nestas diferentes condições. A análise da interrelação entre os sistemas mostrou que uma inibição do proteassoma favorece a via lisossomal e que o inverso não se repete. Os resultados sugerem que a modulação das vias de degradação pode ser interessante para o estudo, prevenção e tratamento das doenças neurodegenerativas associadas à agregação de proteínas / Neurodegenerative diseases, such as Alzheimer\'s, are associated to protein inclusions containing hyperphosphorylated Tau (p-Tau). It is well established that Tau dysfunction impairs cell homeostasis. A key mechanism to prevent and/or reduce the damage promoted by aggregates of Tau might be its degradation. In view of this, the aims of the present study are to evaluate p- Tau clearance following exogenous expression of Bag-2, which stimulates proteasome; as well as to analyze the activation of both lysosome and proteasome pathways in order to understand the crosstalk between these two systems in primary and organotypic cultures of rat hippocampus. Results showed that rotenone was able of increasing p-Tau that was prevented and degraded by Bag-2 overexpression. Mechanisms involved in this process involve the coordination of cell degradation systems, depending upon aggregation status, since Rab7 and Rab24 (involved in lysosomal pathway) were decreased before protein aggregation, while Rab24 increased in the presence of protein inclusions. Amyloid-beta peptide also increased p-Tau accompanied by decreased proteasome and lysosome activity. PADK (lysosomal activator) treatment reverted the inhibition promoted by amyloidbeta peptide. Inhibition of proteasome leads to activation of lysosome, but lysosome inhibition does not affect proteasome. Overall, results suggest that targeting degradation pathways might be useful to understand, prevent and treat neurodegenerative diseases associated with protein deposits

Les maladies neurodégénératives liées à l’âge, telle celle de Parkinson, sont un problème majeur de santé publique. Cependant, la maladie de Parkinson reste incurable et les traitements sont très limités. En effet, les causes de la maladie restent encore mal comprises et la recherche se concentre sur ses mécanismes moléculaires. Dans cette étude, nous nous sommes intéressés à deux phénomènes anormaux se produisant dans la maladie de Parkinson : l’agrégation de l’α-synucléine et l’activation des cellules microgliales. Pour étudier la polymérisation de l’α-synucléine, nous avons établi de nouvelles méthodes permettant la production in vitro de différents types d’oligomères d’α-synucléine. Grâce à des méthodes biophysiques de pointe, nous avons caractérisé ces différents oligomères à l’échelle moléculaire. Puis nous avons étudié leurs effets toxiques sur les neurones. Ensuite, nous nous sommes intéressés à l’activation des microglies et en particulier à leurs canaux potassiques et aux changements liés au vieillissement. Nous avons identifié les canaux Kv1.3 et Kir2.1 et montré qu’ils étaient impliqués dans l’activation des microglies. En parallèle, nous avons établi une méthode originale qui permet l’isolation et la culture de microglies primaires issues de cerveaux adultes. En comparaison à celles de nouveaux-nés, les microglies adultes montrent des différences subtiles mais cruciales qui soutiennent l’hypothèse de changements liés au vieillissement. Globalement, nos résultats suggèrent qu’il est possible de développer de nouvelles approches thérapeutiques contre la maladie de Parkinson en modulant l’action des microglies ou en bloquant l’oligomérisation de l’ α-synucléine. / Age-related neurodegenerative disorders like Parkinson’s disease take an enormous toll on individuals and on society. Despite extensive efforts, Parkinson’s disease remains incurable and only very limited treatments exist. Indeed, Parkinson’s pathogenesis is still not clear and research on its molecular mechanisms is ongoing. In this study, we focused our interest on two abnormal events occurring in Parkinson’s patients, namely α-synuclein aggregation and microglial activation. We first investigated α-synuclein and its abnormal polymerisation. For this purpose, we developed novel methods, which allowed the in vitro production of different types of α-synuclein oligomers. Using highly sensitive biophysical methods, we characterised these different oligomers at a single-particle level. Then, we tested their biological effects on neurons. Afterwards, we studied microglial activation. We concentrated our efforts on two axes, namely age-related changes in microglial function and K+ channels in microglia. We showed that Kv1.3 and Kir2.1 K+ channels are involved in microglial activation. In parallel, we developed a new approach, which allows the effective isolation and culture of primary microglia from adult mouse brains. Adult primary microglia presented subtle but crucial differences in comparison to microglia from neo-natal mice, confirming the hypothesis of age-related changes of microglia. Taken together, our results support the hypotheses that microglial modulation or inhibition of α-synuclein oligomerisation are possible therapeutic strategies against Parkinson's disease.

A alteração do tráfego mitocondrial em neurônios leva ao aumento do estresse oxidativo, privação de energia, deficiência da comunicação intercelular e neurodegeneração. Há evidências de que essas alterações de tráfego antecedem a morte neuronal associada à agregação proteica. Portanto, conhecer a relação entre a mobilidade mitocondrial e a formação de agregados proteicos pode ser um passo importante para o melhor entendimento dos mecanismos da neurodegeneração. Com isso, o objetivo do presente estudo é analisar a mobilidade das mitocôndrias em culturas de células do hipocampo, substância negra e locus coeruleus expostas a rotenona e MPTP, como agentes neurodegenerativos, e à rapamicina como ativador da autofagia. Um outro objetivo do estudo é avaliar o papel do cálcio (através do emprego de EGTA e ionomicina) no modelo experimental. Os resultados mostraram aumento da mobilidade mitocondrial no hipocampo e diminuição na substância negra, já no locus coeruleus houve aumento seguido de diminuição da mobilidade mitocondrial dependendo da concentração de rotenona. O emprego do EGTA e ionomicina mostra que a ação da rotenona sobre o tráfego mitocondrial envolve o cálcio, mas não se relaciona com uma possível alteração da integridade mitocondrial, já que não foi observada alteração no potencial de membrana mitocondrial. Foram também realizados experimentos a fim de avaliar a mobilidade mitocondrial em modelo utilizando rapamicina para ativar a autofagia e MPTP como indutor da neurodegeneração em culturas de células, onde foi observado aumento da mobilidade no hipocampo e no locus coeruleus quando exposto a rapamicina e aumento da mobilidade mitocondrial em cultura de células do hipocampo exposto a MPTP já no locus coeruleus houve uma diminuição significativa da mobilidade mitocondrial. Os resultados permitem concluir que o tráfego mitocondrial está alterado antes da agregação proteica podendo contribuir com a neurodegeneração / Altered mitochondrial traffic in neurons can lead to increased oxidative stress, energy deprivation, impaired intercellular communication and neurodegeneration. There are evidences mitochondria disturbing precedes neuronal death associated with protein aggregation. Therefore, the study of mitochondrial traffic and protein aggregation can be an important step towards a better understanding of the mechanisms of neurodegeneration. Thus, the aim of this study is to analyze mitochondria mobility in cultured cells of the hippocampus, substantia nigra and locus coeruleus exposed to rotenone and MPTP, as neurodegeneration-promoting agents, and rapamycin to activate autophagy. The other objective of the study was to analyze the role of calcium (through EGTA and ionomycin) in the experimental model. The results showed increased and decreased mobility mitochondrial in cells from hippocampus and substantia nigra, respectively, while the locus coeruleus cell culture has increased followed by decreased mitochondrial mobility depending upon rotenone concentration. The use of EGTA and ionomycin showed that alteration of mitochondrial traffic is associated with calcium, however it is not related with changes in mitochondrial membrane potential. Additional experiments were also conducted to assess mitochondrial mobility in a model using rapamycin to activate autophagy and MPTP to induce neurodegeneration in cell cultures. The results of these experiments showed increased mitochondrial mobility in the hippocampus and locus coeruleus when exposed to rapamycin; while MPTP also increased mitochondria mobility in hippocampal cell cultures, but decreased it in locus coeruleus. Results suggest that mitochondrial traffic is altered before protein aggregation, which may contribute to neurodegeneration

O desenvolvimento das doenças neurodegenerativas, como a doença de Alzheimer, está associado à presença de agregados proteicos contendo Tau hiperfosforilada (p-Tau). Esta disfunção da Tau leva a prejuízos na homeostase celular. Um mecanismo chave para diminuir e/ou prevenir os danos promovidos pelos agregados contendo Tau seria o estímulo de sua degradação. Neste sentido, a proposta do presente estudo foi analisar a degradação da proteína Tau após aumento da expressão exógena da cochaperona Bag-2, a qual influencia o sistema proteassomal de degradação; bem como avaliar a ativação dos sistemas de degradação, a fim de correlacionar estes sistemas em cultura de células primárias e organotípica do hipocampo de ratos. Os resultados mostraram que a rotenona foi capaz de aumentar os níveis de p-Tau e que a superexpressão de Bag-2, foi eficiente em prevenir e degradar a p-Tau. O mecanismo envolvido neste processo envolve a coordenação dos sistemas proteassomal e lisossomal, já que a Rab7 e a Rab24 (envolvidas na via lisossomal) mostraram-se diminuídas na fase que antecede a agregação proteica, enquanto houve aumento da Rab24 na presença dos agregados proteicos. Com relação ao peptídeo beta amiloide, foi demonstrado tendência de aumento de p-Tau acompanhado de diminuição da atividade proteassomal e lisossomal. O tratamento com PADK (ativador lisossomal) foi capaz de reverter este efeito nestas diferentes condições. A análise da interrelação entre os sistemas mostrou que uma inibição do proteassoma favorece a via lisossomal e que o inverso não se repete. Os resultados sugerem que a modulação das vias de degradação pode ser interessante para o estudo, prevenção e tratamento das doenças neurodegenerativas associadas à agregação de proteínas / Neurodegenerative diseases, such as Alzheimer\'s, are associated to protein inclusions containing hyperphosphorylated Tau (p-Tau). It is well established that Tau dysfunction impairs cell homeostasis. A key mechanism to prevent and/or reduce the damage promoted by aggregates of Tau might be its degradation. In view of this, the aims of the present study are to evaluate p- Tau clearance following exogenous expression of Bag-2, which stimulates proteasome; as well as to analyze the activation of both lysosome and proteasome pathways in order to understand the crosstalk between these two systems in primary and organotypic cultures of rat hippocampus. Results showed that rotenone was able of increasing p-Tau that was prevented and degraded by Bag-2 overexpression. Mechanisms involved in this process involve the coordination of cell degradation systems, depending upon aggregation status, since Rab7 and Rab24 (involved in lysosomal pathway) were decreased before protein aggregation, while Rab24 increased in the presence of protein inclusions. Amyloid-beta peptide also increased p-Tau accompanied by decreased proteasome and lysosome activity. PADK (lysosomal activator) treatment reverted the inhibition promoted by amyloidbeta peptide. Inhibition of proteasome leads to activation of lysosome, but lysosome inhibition does not affect proteasome. Overall, results suggest that targeting degradation pathways might be useful to understand, prevent and treat neurodegenerative diseases associated with protein deposits